Table 1.
Human gene (chromosomal location) | Mouse gene (chromosomal location) | Expression in normal tissues | Expression in tumours | Activation pathway | Biological function | Disease links | Refs |
---|---|---|---|---|---|---|---|
GSDMA (17q21.1) | Gsdma1–3 (11D) | Gastric and skin epithelia | Silenced in gastric cancer tissues and cell lines | Not known | Not known | Systemic sclerosis in humans, alopecia in mice | 1,27,28,30,31,61 |
GSDMB (17q21.1) | None | Airway, oesophagus, gastrointestinal tract, liver and colon epithelium, neuroendocrine cells, immune cells | Expressed in colon, rectal, pancreatic and cervical cancers, and barely expressed in breast, lung and liver cancers | Granzyme A | Not known | Inflammatory bowel disease, asthma, type I diabetes | 19,32,72,74–80 |
GSDMC (8q24.21) | Gsdmc1–4 (15D1) | Keratinocytes, trachea, spleen, oesophagus, small intestine, caecum, and colon | Upregulated in colorectal cancer and melanoma | TNFR–caspase 8 | Not known | Not known | 20,82–85 |
GSDMD (8q24.3) | Gsdmd (15D3-E1) | Immune cells, placenta, oesophagus and gastrointestinal tract epithelium | Expressed in oesophageal and gastric, pancreatic, prostate cancers, melanoma, salivary gland tumours, Jurkat T cells, Ramos B cells | Inflammasome inflammatory caspases; neutrophil elastase; cathepsin G; RIPK1–caspase 8 | Pyroptosis; NETosis | Sepsis, experimental autoimmune encephalomyelitis, macular degeneration, neonatal onset multisystem inflammatory disease | 13,14,25,43,105,106,131,144 |
GSDME (7p15.3) (a.k.a. DFNA5) | Gsdme (6B2.3) (a.k.a. Dfna5) | Cochlea, placenta, heart, brain, kidney | Epigenetically inactivated by DNA methylation in gastric, colorectal and breast cancer, and most human cancer cell lines | Granzyme B, caspase 3 | Pyroptosis | Autosomal dominant nonsyndromic hearing loss | 16–18,33–38 |
DFNB59 (2q31.2) (a.k.a. PJVK) | Dfnb59 (2C3) (a.k.a. Pjvk) | Brain, eye, inner ear, heart, lung, kidney, liver, intestine, testis | Not known | Not known | Hair cell maintenance | Recessive nonsyndromic hearing impairment | 39 |
a.k.a., also known as.